학술논문
First-in-human study of novel SSTR antagonist 177 Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, safety and efficacy
Document Type
Article
Author
Source
In: Journal of Nuclear Medicine . (Journal of Nuclear Medicine, 1 November 2021, 62(11))
Subject
Language
English
ISSN
2159662X
01615505
01615505